Insider · CIK 0001716950
Matthew Feinsod
officer
Files at KLRS (Kalaris Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 10, 2025 | KLRS Kalaris Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +70,551 | $0.00 | $0 | 70,551 | Apr 11, 2025 |
| Apr 10, 2025 | KLRS Kalaris Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +101,000 | $0.00 | $0 | 101,000 | Apr 11, 2025 |
| Mar 18, 2025 | KLRS Kalaris Therapeutics, Inc. | AGrant or award Common Stock | +4,030 | - | - | 4,030 | Mar 18, 2025 |
| Mar 18, 2025 | KLRS Kalaris Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +28,224 | - | - | 28,224 | Mar 18, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.